Zhiping Ye

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. pmc Association of influenza virus matrix protein with ribonucleoproteins
    Z Ye
    Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 73:7467-73. 1999
  2. pmc Targeted infection of HIV-1 Env expressing cells by HIV(CD4/CXCR4) vectors reveals a potential new rationale for HIV-1 mediated down-modulation of CD4
    Zhiping Ye
    Molecular Virology and Neurogenetics Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 9403, USA
    Retrovirology 2:80. 2005
  3. doi request reprint A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA
    J Infect Dis 200:1874-83. 2009
  4. doi request reprint Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Infect Dis 53:1179-87. 2011
  5. doi request reprint Genetic contributions to influenza virus attenuation in the rat brain
    Li Qi
    CBER, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Neurovirol 14:136-42. 2008
  6. pmc Introduction of a temperature-sensitive phenotype into influenza A/WSN/33 virus by altering the basic amino acid domain of influenza virus matrix protein
    Teresa Liu
    Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Virol 78:9585-91. 2004
  7. pmc Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2
    Wei Wang
    Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1002081. 2011
  8. doi request reprint A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity
    Wei Wang
    Laboratory of Immunoregulation, US Food and Drug Administration, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Virology 407:374-80. 2010
  9. pmc Rapid detection and differentiation of swine-origin influenza A virus (H1N1/2009) from other seasonal influenza A viruses
    Jiangqin Zhao
    Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Viruses 4:3012-9. 2012
  10. doi request reprint Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays
    Wei Wang
    Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, United States
    J Virol Methods 165:305-10. 2010

Collaborators

Detail Information

Publications30

  1. pmc Association of influenza virus matrix protein with ribonucleoproteins
    Z Ye
    Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 73:7467-73. 1999
    ..The data suggest that M1 interacts with both the RNA and protein components of RNP in assembly and disassembly of influenza A viruses...
  2. pmc Targeted infection of HIV-1 Env expressing cells by HIV(CD4/CXCR4) vectors reveals a potential new rationale for HIV-1 mediated down-modulation of CD4
    Zhiping Ye
    Molecular Virology and Neurogenetics Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 9403, USA
    Retrovirology 2:80. 2005
    ....
  3. doi request reprint A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, USA
    J Infect Dis 200:1874-83. 2009
    ..Our study suggests an alternative approach to attenuate wt influenza viruses for the development of a pandemic vaccine with broad cross-protection...
  4. doi request reprint Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Infect Dis 53:1179-87. 2011
    ..Approximately 45 million people in the United States were vaccinated against NJ/76 30 years ago, but the impact of this nationwide immunization on the current pandemic is largely unknown...
  5. doi request reprint Genetic contributions to influenza virus attenuation in the rat brain
    Li Qi
    CBER, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Neurovirol 14:136-42. 2008
    ..Further in vivo and in vitro examination of these five mutations, both individually and in combination, will likely provide important information on the role of specific virus genes in virulence and pathogenesis...
  6. pmc Introduction of a temperature-sensitive phenotype into influenza A/WSN/33 virus by altering the basic amino acid domain of influenza virus matrix protein
    Teresa Liu
    Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Virol 78:9585-91. 2004
    ..The R101S-R105S double mutant had a greatly reduced ratio of M1 to NP in viral particles and a weaker binding of M1 to RNPs. These results suggest that mutations can be introduced into the RKLKR domain to control viral replication...
  7. pmc Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2
    Wei Wang
    Laboratory of Immunoregulation, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1002081. 2011
    ..These findings highlight a cross-neutralization determinant influenced by a point mutation in HA2 and suggest that HA2 may be evolving under direct or indirect immune pressure...
  8. doi request reprint A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity
    Wei Wang
    Laboratory of Immunoregulation, US Food and Drug Administration, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Virology 407:374-80. 2010
    ..None of these modifications affected neutralization. These findings provide information for increasing 2009 H1N1HA-pseudotype titers without altering antigenicity and offer insights into receptor use...
  9. pmc Rapid detection and differentiation of swine-origin influenza A virus (H1N1/2009) from other seasonal influenza A viruses
    Jiangqin Zhao
    Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Viruses 4:3012-9. 2012
    ..This new method may be useful for simultaneous detection and subtyping of influenza A viruses and can be rapidly modified to detect other emerging influenza strains in public health settings...
  10. doi request reprint Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays
    Wei Wang
    Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, United States
    J Virol Methods 165:305-10. 2010
    ..These findings support continued development of HA-pseudotypes as a robust tool for analyzing sera in vaccine and serologic studies...
  11. pmc Attenuating mutations of the matrix gene of influenza A/WSN/33 virus
    Teresa Liu
    Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    J Virol 79:1918-23. 2005
    ..The replication and attenuating properties of R101S-R105S suggest its potential in development of live influenza virus vaccines...
  12. doi request reprint Increased hemagglutinin content in a reassortant 2009 pandemic H1N1 influenza virus with chimeric neuraminidase containing donor A/Puerto Rico/8/34 virus transmembrane and stalk domains
    Xianghong Jing
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, United States Food and Drug Administration, Bethesda, MD, USA
    Vaccine 30:4144-52. 2012
    ..Therefore, we propose that the reduction of NA packaging in the virion may lead to a compensatory increase of HA. Such an improvement in HA yield is possibly beneficial to H1N1 pdm09 vaccine production...
  13. ncbi request reprint Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid
    Hang Xie
    Laboratory of Pediatric and Respiratory Virus Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, United States
    Vaccine 25:7649-55. 2007
    ..Furthermore, pHA/M1 immunization resulted in improved protection against both homologous and heterologous challenges...
  14. doi request reprint Mutations to A/Puerto Rico/8/34 PB1 gene improves seasonal reassortant influenza A virus growth kinetics
    Ewan P Plant
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States
    Vaccine 31:207-12. 2012
    ....
  15. pmc Stability and infectivity of novel pandemic influenza A (H1N1) virus in blood-derived matrices under different storage conditions
    Xue Wang
    Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, CBER FDA, Bethesda, MD 20892, USA
    BMC Infect Dis 11:354. 2011
    ..Furthermore the effect of storage on virus stability and infectivity has not been well studied...
  16. pmc Optimizing viral protein yield of influenza virus strain A/Vietnam/1203/2004 by modification of the neuraminidase gene
    Joan E Adamo
    Division of Viral Products, CBER, US Food and Drug Administration, Rockville Pike, Bethesda, Maryland 20892, USA
    J Virol 83:4023-9. 2009
    ..The relationship between the infectivity and protein yield of the reassortants also is discussed...
  17. pmc Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007
    ..This M2 prime-boost vaccination conferred broad protection against challenge with lethal influenza A, including an H5N1 strain. Vaccination with M2, with key sequences represented, may provide broad protection against influenza A...
  18. pmc Comparative glycomics analysis of influenza Hemagglutinin (H5N1) produced in vaccine relevant cell platforms
    Yanming An
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Proteome Res 12:3707-20. 2013
    ....
  19. doi request reprint Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies
    Wei Wang
    Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, USA
    J Virol Methods 153:111-9. 2008
    ....
  20. pmc Restriction of viral replication by mutation of the influenza virus matrix protein
    Teresa Liu
    Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Food and Drug Administration, Building 29A, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 76:13055-61. 2002
    ..In contrast, deletion of RKLKR or substitution of Lys with Asn at position 102 or 104 of RKLKR resulted in a lethal mutation. These results indicate that the RKLKR domain of M1 protein plays an important role in viral replication...
  21. ncbi request reprint Association of influenza virus matrix protein with ribonucleoproteins may control viral growth and morphology
    Teresa Liu
    Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics and Evaluation and Research, Food and Drug Administtration, Bethesda, Maryland 20892, USA
    Virology 304:89-96. 2002
    ..These studies indicate that the binding between M1 and RNP complex might determine viral growth and morphology...
  22. ncbi request reprint Highly pathogenic avian influenza A virus (H5N1) can be transmitted in ferrets by transfusion
    Xue Wang
    Lab of Molecular Virology, Building 29B, Rm 4NN22, Division of Emerging and Transfusion Transmitted Diseases, CBER FDA, 8800 Rockville Pike, Bethesda, MD 20892, USA
    BMC Infect Dis 14:192. 2014
    ..The infectivity of virus in blood and the potential for virus transmission by transfusion has not been investigated...
  23. doi request reprint Assessment of viral replication in eggs and HA protein yield of pre-pandemic H5N1 candidate vaccine viruses
    Xianghong Jing
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, United States Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, United States
    Vaccine 31:4091-7. 2013
    ..Our studies on the HA protein purification may improve the quality control of the production of influenza vaccine test reagent...
  24. doi request reprint Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin
    Falko Schmeisser
    Division of Viral Products, Center for Biologics Evaluations and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Influenza Other Respir Viruses 7:480-90. 2013
    ..The antibodies were specific for the A/California/04/2009 HA, and individual mAbs suitable for use in several practical applications including ELISA, immunofluorescence, and Western blot analysis were identified...
  25. pmc Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly
    Hang Xie
    Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, United States Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 6:e16650. 2011
    ..The pandemic specific cross-reactive antibodies strongly correlated with the post-vaccination HAI titers against the seasonal H3N2 vaccine strain in all subjects...
  26. ncbi request reprint Wild-type and attenuated influenza virus infection of the neonatal rat brain
    Steven Rubin
    DVP OVRR CBER FDA, Bethesda, Maryland 20892, USA
    J Neurovirol 10:305-14. 2004
    ....
  27. pmc Viremia associated with fatal outcomes in ferrets infected with avian H5N1 influenza virus
    Xue Wang
    Lab of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS ONE 5:e12099. 2010
    ..Our observations further substantiate pathogenicity of H5N1 and further indicate that viremia may be a bio-marker for fatal outcomes in H5N1 infection...
  28. ncbi request reprint Generation of the influenza B viruses with improved growth phenotype by substitution of specific amino acids of hemagglutinin
    Vladimir Y Lugovtsev
    Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Virology 365:315-23. 2007
    ..The results of our studies demonstrate that introduction of specific AA substitutions into viral HA can improve viral replicative efficiency while preserving the original antigenic properties...
  29. pmc Multiplexed, rapid detection of H5N1 using a PCR-free nanoparticle-based genomic microarray assay
    Jiangqin Zhao
    Lab of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    BMC Biotechnol 10:74. 2010
    ....
  30. ncbi request reprint Mouse neurotoxicity test for vaccinia-based smallpox vaccines
    Zhongqi Li
    Laboratory of Pediatric and Respiratory Viral Diseases, OD Center for Biologics Evaluation and Research, Food and Drug Administration, HFM 460, Bldg 29B, Room 5NN22, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Vaccine 22:1486-93. 2004
    ..With further validation, this assay incorporating a licensed vaccine reference standard and positive control strain may provide important pre-clinical neurotoxicity data on new vaccinia-based smallpox vaccine strains...